Fig. 5.

Validation of the biomarkers of drug sensitivity in vivo. a, b Change in tumor volume following treatment with palbociclib at three doses in ZEC145 PDCX CDKN2A/2B loss tumors (28 days) and in ZEC166 PDCX CDKN2A/2B-WT tumors (17 days) (mean ± s.e.m., n = 10). c, d General picture of ZEC145 PDCXs and ZEC166 PDCXs after intragastric administration of palbociclib (10 mice per dose). Error bars correspond to standard error of the mean of tumor volume. *p < 0.01, Student’s t test, palbociclib 0 mg/kg compared with palbociclib 75 mg/kg; *p < 0.01, Student’s t test, palbociclib 75 mg/kg compared with palbociclib 150 mg/kg